Last €0.46 EUR
Change Today +0.002 / 0.44%
Volume 0.0
EYJ On Other Exchanges
As of 2:08 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

qrxpharma ltd (EYJ) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/6/13 - €0.97
52 Week Low
12/17/13 - €0.38
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for QRXPHARMA LTD (EYJ)

Related News

No related news articles were found.

qrxpharma ltd (EYJ) Related Businessweek News

No Related Businessweek News Found

qrxpharma ltd (EYJ) Details

QRxPharma Limited, a specialty pharmaceutical company, develops and commercializes biopharmaceutical products primarily in Australia. The company’s pain management products include MOXDUO, which is an immediate-release oral capsule for the treatment of moderate to severe acute pain; Q8011, a controlled-release oral tablet that is a proprietary morphine/oxycodone formulation in Phase II clinical trials to provide analgesia in patients suffering from moderate to severe chronic pain; and Q8012, an intravenous dual opioid formulation of morphine and oxycodone, which has completed Phase II trial for acute moderate to severe hospital-based pain. It has a collaboration agreement with Aesica Formulation Development Limited for the promotion of its proprietary Stealth Beadlets abuse deterrence technology. QRxPharma Limited is based in North Sydney, Australia.

qrxpharma ltd (EYJ) Top Compensated Officers

Chief Executive Officer, Managing Director, C...
Total Annual Compensation: A$401.2K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$219.7K
Chief Operating Officer
Total Annual Compensation: A$337.3K
Senior Vice President of Global Business Deve...
Total Annual Compensation: A$286.9K
Compensation as of Fiscal Year 2013.

qrxpharma ltd (EYJ) Key Developments

QRxPharma Limited Reports Consolidated Earnings Results for the Half-Year Ended December 31, 2013

QRxPharma Limited reported consolidated earnings results for the half-year ended December 31, 2013. For the period, the company reported from continuing operations and net loss attributable to owners of the company of AUD 5.1 million or 3.5 cents per basic and diluted share compared to a net loss of AUD 5.2 million or 3.6 cents per basic and diluted share for the half-year ended December 31, 2012. The net loss for the period from ordinary activities resulted from the company's continuing efforts to secure approval for immediate release Moxduo. The company reported revenue from continuing operations of AUD 620,000 compared to AUD 2,235,000, loss before income tax of AUD 5,132,000 compared to AUD 5,209,000, net cash outflow from operating activities of AUD 5,962,000 compared to AUD 6,035,000 and payments for property, plant and equipment payments for property, plant and equipment of AUD 60,000 compared to AUD 9,000 for the last year.

QRxPharma Limited Announces Change of the Address of its Registered Office

QRxPharma Limited has changed the address of its registered office and principal administrative office to Level 11, Suite 1, 100 Walker Street, North Sydney NSW 2060, Australia.

QRxPharma Limited Presents at 8th Annual BIO Europe Spring 2014, Mar-12-2014 12:30 PM

QRxPharma Limited Presents at 8th Annual BIO Europe Spring 2014, Mar-12-2014 12:30 PM. Venue: OVAL Lingotto, Turin, Italy.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EYJ:GR €0.46 EUR +0.002

EYJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EYJ.
View Industry Companies

Industry Analysis


Industry Average

Valuation EYJ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 40.9x
Price/Book 7.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 39.3x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QRXPHARMA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at